Assertio Therapeutics Announces First-Quarter 2020 Results
-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger with Zyla Life Sciences On Track and Expected to Close …